EGFR and melanoma: In addition to NRAS mutations, several receptor tyrosine kinases (RTKs) such as c-KIT, EGFR, MET, and VEGFR have been reported to be involved in melanoma progression, invasion, or resistance to therapies, mainly targeting the MAPK pathway [20,121,204].